EUVIMEDEUVIMED entdecken
Crossref

Fingolimod ( FTY720 ), an FDA ‐approved sphingosine 1‐phosphate ( S1P ) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection

Ayan Modak, Srishti Rajkumar Mishra, Mansi Awasthi, Arya Aravind, Sneha Singh, Easwaran Sreekumar iD

IUBMB Life · 2024

DOI: 10.1002/iub.2795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2024. Verfasst von Ayan Modak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Virology Laboratory, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Dengue Virus, Dengue, Endothelial Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensive vascular leakage and shock is a major cause of dengue‐associated mortality. At present, there are no specific treatments available. Sphingolipid pathway is a key player in the endothelial barrier integrity; and is mediated through the five sphingosine‐1‐phosphate receptors (S1PR1‐S1PR5). Signaling through S1PR2 promotes barrier disruption; and in Dengue virus (DENV)‐infection, there is overexpression of this receptor. Fingolimod (FTY720) is a specific agonist that targets the remaining barrier‐protective S1P receptors, without targeting S1PR2. In the present study, we explored whether FTY720 treatment can alleviate DENV‐induced endothelial hyperpermeability. In functional assays, in both in vitro systems and in AG129 animal models, FTY720 treatment was found effective. Upon treatment, there was complete restoration of the monolayer integrity in DENV serotype 2‐infected human microvascular endothelial cells (HMEC‐1). At the molecular level, the treatment reversed activation of the S1P pathway. It significantly reduced the phosphorylation of the key molecules such as PTEN, RhoA, and VE‐Cadherin; and also, the expression levels of S1PR2. In DENV2‐infected AG129 mice treated with FTY720, there was significant improvement in weight gain, in overall clinical symptoms, and in survival. Whereas 100% of the DENV2‐infected, untreated animals died by day‐10 post‐infection, 70% of the FTY720‐treated animals were alive; and at the end of the 15‐day post‐infection observation period, 30% of them were still surviving. There was a significant reduction in the Evan's‐blue dye permeability in the organs of FTY720‐treated, DENV‐2 infected animals; and also improvement in the hemogram, with complete restoration of thrombocytopenia and hepatic function. Our results show that the FDA‐approved molecule Fingolimod (FTY720) is a promising therapeutic intervention in severe dengue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideDengue VirusDengueEndothelial CellsCapillary PermeabilitySphingosine 1 Phosphate Receptor ModulatorsReceptors, LysosphingolipidAnimalsHumansSphingosine-1-Phosphate ReceptorsMiceDisease Models, AnimalCadherinsSignal TransductionAntigens, CDCadherin 5

Stichwörter der Autor:innen

FITC‐dextrandengueendotheliumtrans‐endothelial electrical permeability (TEER)

Substanzen

Fingolimod HydrochlorideSphingosine-1-Phosphate ReceptorsSphingosine 1 Phosphate Receptor ModulatorsCadherinsReceptors, LysosphingolipidAntigens, CDCadherin 5

Autor:innen und Institutionen

  • Molecular Virology Laboratory, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India.
  • Regional Centre for Biotechnology (RCB), NCR Biotech Science Cluster, Faridabad, Haryana (NCR Delhi), India.
  • Animal Research Facility, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, India.
  • Molecular Bioassay Laboratory, Institute of Advanced Virology (IAV), Thiruvananthapuram, Kerala, India.

ORCID-Profile: Easwaran Sreekumar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Modak, A., Mishra, S. R., Awasthi, M., Aravind, A., Singh, S., & Sreekumar, E. (2024). Fingolimod ( FTY720 ), an FDA ‐approved sphingosine 1‐phosphate ( S1P ) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection. IUBMB Life. https://doi.org/10.1002/iub.2795

Vancouver

Modak A, Mishra SR, Awasthi M, Aravind A, Singh S, Sreekumar E. Fingolimod ( FTY720 ), an FDA ‐approved sphingosine 1‐phosphate ( S1P ) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection. IUBMB Life. 2024. doi:10.1002/iub.2795

BibTeX
@article{Modak2024,
  author = {Modak, Ayan and Mishra, Srishti Rajkumar and Awasthi, Mansi and Aravind, Arya and Singh, Sneha and Sreekumar, Easwaran},
  title = {Fingolimod ( FTY720 ), an FDA ‐approved sphingosine 1‐phosphate ( S1P ) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection},
  journal = {IUBMB Life},
  year = {2024},
  doi = {10.1002/iub.2795}
}
Kostenlos starten →